OssDsign’s Management and Board of Directors increase their long-term commitment through acquisiton of warrants for a total amount of approximately SEK 1.3 million
Uppsala, Sweden, 08.00 CET, 1 July 2021 – OssDsign, a global provider of regenerative orthopedic solutions for treatment of patients who have suffered from cranial or spinal bone defects, today announces that its Management and Board of Directors have acquired 3.8m warrants under the 2021/2024 long-term incentive programme for a total amount of approximately SEK 1.3 million.The largest individual participants in the incentive programme are the company’s CEO, CFO and Chairman: · Morten Henneveld (CEO) has aquired 1,712,235 warrants at an approximate cost of SEK 600 000 · Anders